CEO Damien McDevitt, PhD, Featured in Biocom’s Article, “A Look at the Year Ahead for Life Sciences.”
Aspen Neuroscience’s CEO, Damien McDevitt, PhD, was featured in Biocom California’s article, “A Look at the Year Ahead for Life Sciences.” Damien states, “The lack of treatment options for patients with neurodegenerative diseases remains a significant unmet medical need, especially…
Kim Raineri and Andrés Bratt-Leal, PhD, presented at Phacilitate Advanced Therapies Week
Aspen Neuroscience’s Co-Founder and Senior Vice President of Research and Development, Andrés Bratt-Leal, PhD, and Chief Technology Officer, Kim Raineri, presented at the Advanced Therapies Week session, “Cell and Gene Therapy for Neurological Indications” on Friday, January 20th.
Aspen Neuroscience Selected as a Finalist for the Phacilitate Biotech Innovation Award
Aspen Neuroscience was selected as a finalist for the Biotech Innovation Award at the Advanced Therapies Awards at Phacilitate Advanced Therapies Week.
Aspen Neuroscience’s Thorsten Gorba, PhD, and Xiaokui Zhang, PhD, Presented at the iPSC-Derived Cell Therapies Summit
Aspen Neuroscience’s Chief Scientific Officer Xioakui Zhang, PhD, served as a panel member at the annual iPSC-Derived Cell Therapies Summit in Boston during “Industry Leaders’ Fireside Chat: Taking a Look at the Current Learnings from iPSC-Derived Cell Therapies & Determining Future Outlook…
Aspen Neuroscience will Present at the Annual iPSC-Derived Cell Therapies Summit
We are looking forward to presenting this week at the annual iPSC-Derived Cell Therapies Summit in Boston. Xiaokui Zhang, PhD, Aspen’s Chief Scientific officer will serve as a panel member on Tuesday, December 6th at 8:30 a.m. during “Industry Leaders’ Fireside…
Aspen Neuroscience’s David Tastad, PhD, Presented at the Annual Society for Neuroscience Meeting
Aspen Neuroscience’s David Tastad, PhD, presented the poster “Dopamine Neuron Regulation,” at the annual Society for Neuroscience (SFN) meeting on Sunday, November 13th. The presentation explored functional characterization of GBA1 mutations in iPSC-derived midbrain dopaminergic neurons. “There was a great…
Aspen Neuroscience Pursues Autologous Cell Therapies for Parkinson’s with $147.5M Series B
The Scripps Research spinout eyes 2023 for dosing of its first patients with its first product, designed to treat idiopathic Parkinson’s disease.
Aspen Neuroscience collects large Series B to compete against Bayer’s Parkinson’s cell therapy
Damien McDevitt thinks frequently about the name Aspen Neuroscience. Specifically, should the neuroscience portion be dropped as the San Diego biotech considers expanding beyond the CNS?
An Autologous Stem Cell-Based Therapy for Parkinson’s Disease
Cell therapies hold great promise to treat Parkinson’s disease, but there’s an ongoing debate over how to best do this. One group—and I am firmly in this camp—maintains an autologous therapy, derived from a patient’s own cells, is the correct…
Aspen Neuroscience Gets $70 Million Series A Funding Round
Aspen Neuroscience, a private biotech company developing the first autologous neuron replacement therapy to treat Parkinson’s disease, announced the close of its Series A funding round of $70 million. OrbiMed led the investment round with participation from ARCH Venture Partners,…